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Based on U.S. claims data, we assigned doctors IDs based on the physician who treated 
the enrollee for the longest period of time after eliminating any emergency room, labo-
ratory, and radiology services. Physician prescribing patterns were then calculated 
from prescription drug records. Patients were grouped as generic SSRIs, non-generic 
SSRIs, and SNRIs. RESULTS: We identiﬁed the doctors’ prescribing pattern with the 
percentage of time they prescribed SSRIs, non-generic SSRIs and SNRIs. We showed 
that patients were more likely to be prescribed generic SSRIs relative to non-generic 
SSRIs if doctors’ prescribing patterns favored generic prescription (p = 0.000). Simi-
larly, patients were less likely to be in the SSRIs group if doctors’ prescribing patterns 
favored SNRI prescription (p = 0.000). CONCLUSIONS: Doctors’ prescribing pat-
terns are important factors for decisions on treatment. Any outcomes models (compli-
ance, or treatment effect on health care utilization and cost) should control for these 
patterns.
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OBJECTIVES: Application of a segmented times series model to measure the effect of 
guidelines on outcomes measures. METHODS: To isolate the effect of guidelines, we 
need to control for three different factors: 1) Baseline differences between the two 
groups, 2) Step-wise differences at the intervention point, and 3) Trend differences 
after the intervention. The segmented times series model was combined with the 
propensity score matching technique. The segmented time series model contained two 
predictor variables: the binary intervention variable and an interval coding for time. 
The kitchen sink approach was used for propensity score matching and the segmented 
time series model controlled for the confounding inﬂuence of any underlying trend. 
The ﬁnal model ensured that any estimated change in the mean level of the series after 
intervention was not simply due to the series’ trend. RESULTS: Using U.S. claims data, 
we analyzed the effect of the American Psychiatric Association’s consensus statement 
on glucose monitoring for patients on atypical antipsychotic drugs. Glucose screening 
rose 1% per quarter among antipsychotic-treated patients before release of the guide-
lines, compared to 0.5% per quarter after (P = 0.005 for trend). Monitoring rates 
were 16.07% before release of the guidelines and 18.76% after (P < 0.001). CONCLU-
SIONS: The segmented time series model can provide a clear picture about both trend 
and intervention effect when analyzing the effects of guidelines.
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AGREEMENT BETWEEN PATIENTS WITH MILD DEMENTIA AND 
CAREGIVERS ON THE PROMIS CAT MEASURE OF PERCEIVED 
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OBJECTIVES: The PROMIS measure of Perceived Cognitive Function has gone 
through multiple cycles of development and validation testing, but has not been 
extensively tested in clinical settings, particularly among patients being treated for 
neurological conditions and/or cognitive deﬁcits. We sought to do an initial examina-
tion of the extent to which patients being treated for mild dementia and their caregiv-
ers would agree in their assessment of patient cognitive function using the PROMIS 
PCF measure. METHODS: A total of 14 consecutive patients being seen in the Neurol-
ogy outpatient clinic at Henry Ford Hospital for a diagnosis of dementia, as well as 
one adult caregiver per patient, were invited to complete the PROMIS Perceived 
Cognitive Function CAT measure in reference to the patient’s current level of cognitive 
function. Several analyses of agreement between caregiver and patient reports were 
conducted. RESULTS: All patients and all caregivers were able to successfully com-
plete the PROMIS PCF measure. There was no signiﬁcant difference between patients 
and caregivers in either mean raw score, mean T-score, or standard error for the 
measure. The score ranges for caregivers and patients were quite comparable. The 
Pearson correlation coefﬁcients for association between patient and caregiver 
responses were .246 and .286 for raw score and t-score, respectively (both n.s.). 
CONCLUSIONS: The lack of signiﬁcant difference between patients and caregivers 
on mean response suggests possible validity of the PCF measure for group-level analy-
ses, but the relatively low correlations between patient and caregiver suggest caution 
about use of the measure at the individual patient level. The next step of analysis will 
involve comparison of patient PCF scores to scores on objective measures of cognitive 
function.
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OBJECTIVES: RA is a systemic disease resulting in comorbidities that affect quality 
of life, prognosis and outcomes. Comorbid illnesses can impact treatment, medical 
costs, disability and risk of mortality. Rheumatoid Arthritis Outcomes Analyzer, a 
validated claims data analysis tool with a user-friendly interface was used to character-
ize comorbidities in patients with RA. METHODS: The study included patients age 
18 or older with at least 2 diagnoses of RA (ICD-9 CM 714.0X) ≥ 2 months apart 
between January 2005 and December 2007 from the HealthCore Integrated Research 
DatabaseSM. Patients must have received ≥ one traditional (non-biologic) or biologic 
DMARD medication with RA diagnoses at least two months apart. All medical and 
pharmacy claims were entered into the ﬁnal dataset. RESULTS: A total of 25,856 RA 
patients entered into the analysis (mean age = 56; 74.8% female). The overall mean 
Charlson Comorbidity Index (CCI) was 2.00 (SD = 1.63) and was higher for males 
(mean = 2.18; SD = 1.85) than females (mean = 1.94; SD = 1.55). In the 18 to 44 age 
group, females tended to have a higher CCI (mean = 1.38; SD = 0.91) than males 
(mean = 1.30; SD = 0.81). This trend reverses in older patients where the mean CCI 
in males in the 45 to 64 and ≥ 65 age groups is 1.90 (SD = 1.50) and 3.31 (SD = 2.39) 
respectively versus 1.76 (SD = 1.29) and 2.80 (SD = 2.07) in females. The most fre-
quent comorbid conditions for all patients were; chronic pulmonary disease, diabetes, 
cerebrovascular disease, tumor, congestive heart failure, peripheral vascular disease 
and renal disease. CONCLUSIONS: This analysis explores and differentiates the CCI 
by gender and age group in patients with RA using a validated claims data analysis 
tool. Further study will examine the relationship between comorbidity and health-
related and cost outcomes.
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OBJECTIVES: We sought to conduct a statistical mapping analysis between a stan-
dard investigator assessment of disease severity in ankylosing spondylitis (AS) and 
domain responses in a standard index of health utility; and secondly, to implement 
the above mapping in an optimised algorithm to estimate utility. METHODS: Multi-
nomial logistic regression was used to estimate response probabilities to each domain 
of the EQ5D from the Bath Ankylosing Spondylitis Metrology Index (BASMI) among 
patients enrolled into an RCT studying the use of either etanercept infusion vs. oral 
sulphasalazine (ASCEND). Other covariates tested were gender, age, co-morbidity, AS 
duration, DMARD history, and concurrent medications. Predicted EQ5Dindex was 
estimated by Monte Carlo bootstrap simulation. The predictive ability of the response 
mapping was assessed by comparing estimated and directly measured utility derived 
from the UK tariff. RESULTS: Evaluable data were available for 566 predominantly 
white (87%) patients, 74% of whom male, with a mean baseline age of 41 years (sd 
12) and median AS duration 4 years (IQR 1 to 11). Average BASMIlinear was 4.1 (sd 
1.8) whilst median observed EQ5D utility was 0.587 (IQR 0.193 to 0.691). The linear 
deﬁnition of the BASMI was optimal in an algorithm that also adjusted for gender, 
AS duration, number of co-morbid body systems, number of historic DMARDs, 
number of current non-DMARD drugs, and current NSAID use. The mean utility 
predicted by the optimized algorithm was 0.552 (sd 0.101) and 0.559 (sd 0.295) by 
estimation directly from EQ5D responses (p = 0.238). The mean squared error 
between the actual and predicted utilities was 0.076 (sd 0.111). Adjusted utility was 
deﬁned by −0.044*BASMIlinear+0.715, with an R2 of 0.62. CONCLUSIONS: In this 
study, response mapping of AS disease activity to the EQ5Dindex produced reliable 
estimates of preference-based health-related utility. Future analysis will compare the 
relative ability of patient-reported, AS-speciﬁc, functional assessment measures in 
predicting health-related utility.
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OBJECTIVES: The aim of this study was to evaluate the effectiveness of ﬁve bisphos-
phonates approved for the treatment of postmenopausal osteoporosis. METHODS: 
Randomized placebo controlled studies describing the occurrence of clinical vertebral 
(CVF), morphometric vertebral (MVF) and nonvertebral fractures (NVF) were identi-
ﬁed by searching the Cochrane Database, International Pharmaceutical Abstracts and 
Ovid Medline. Studies were eligible if patients had suffered a fracture at entry or had 
a bone mineral density at least 2 SD below the mean value for young adult females. 
WinBUGS was used to conduct the analysis, which permitted combining direct and 
indirect evidence to rank order the treatments. RESULTS: A total of 39 studies were 
identiﬁed. All ﬁve bisphosphonates were found to reduce the relative risk of new 
fractures in women with postmenopausal osteoporosis. For CVF, all ORs for treat-
ments compared to placebo were statistically signiﬁcant, suggesting that treatment 
with any agent is better than none. Zoledronate was the most effective treatment (OR 
= 0.22, 95%CRI:0.13–0.36), followed by both alendronate (OR = 0.48, 95%CRI:0.30–
0.76) and ibandronate (OR = 0.51, 95%CRI:0.34–0.77) as these could not be dif-
ferentiated statistically (no data were available for etidronate and risedronate). For 
MVF also, all ORs for treatments compared to placebo were statistically signiﬁcant. 
Zoledronate (OR = 0.28, 95%CRI:0.22–0.35) and etidronate (OR = 0.29, 
95%CRI:0.17–0.48) were both most effective, followed by alendronate (OR = 0.52, 
95%CRI:0.42–0.64), risedronate (OR = 0.56, 95% 0.45–0.70) and ibandronate (OR 
= 0.67, 95% 0.54–0.83); The last three could not be differentiated. For NVF the ORs 
for zoledronate (OR = 0.70, 95%CRI:0.60–0.80), risedronate (OR = 0.71, 
